Adverse Drug Reaction Classification System

Pharmaceutical Information
Drug Name Nabumetone
Drug ID BADD_D01511
Description Nabumetone was originally developed as a non-acidic non-steroidal anti-inflammatory drug (NSAID).[label] It was thought to avoid trapping of the drug in the stomach by making it unable to dissociate into ions which was believed to reduce GI toxicity by limiting local action.[A179077] While slightly reduced, possibly due to a degree of cyclooxygenase-2 selectivity (COX-2), nabumetone still produces significant adverse effects in the GI tract.[label,A178903] The molecule itself is a pro-drug with its 6-methoxy-2-naphthylacetic acid (6-MNA) metabolite acting as a potent COX inhibitor similar in structure to [naproxen]. Nabumetone was developed by Smithkline Beecham under the trade name Relafen and first received FDA approval in December, 1991.[L6568]
Indications and Usage **Indicated** for:[label] 1) Symptomatic relief in rheumatoid arthritis. 2) Symptomatic relief in osteoarthritis.
Marketing Status approved
ATC Code M01AX01
DrugBank ID DB00461
KEGG ID D00425
MeSH ID D000077430
PubChem ID 4409
TTD Drug ID D05CKR
NDC Product Code 49706-0681; 62331-008; 45865-464; 50090-6167; 60760-369; 60760-386; 62135-145; 0591-3671; 80425-0054; 65977-0082; 50228-465; 51655-733; 62135-146; 63629-8508; 69097-966; 72189-184; 76282-257; 15370-170; 69097-965; 71205-978; 71335-1234; 72189-072; 55700-845; 76420-210; 24196-135; 60687-630; 60760-368; 63187-307; 63629-8506; 69367-241; 69367-242; 0591-3670; 79739-7077; 50090-5386; 50228-466; 53002-6960; 61919-668; 68788-7597; 68788-7765; 79739-7076; 80425-0104; 65015-632; 43063-972; 45865-111; 50090-5294; 51655-446; 60760-387; 63187-378; 63629-7699; 63629-8509; 71335-1272; 71335-1391; 45865-997; 55700-840; 61919-609; 71335-1559; 63629-8510; 76282-258; 80425-0053; 63187-484; 71205-030; 71205-530; 71205-977; 72789-040; 79739-7078
UNII LW0TIW155Z
Synonyms Nabumetone | Nabumeton | 4-(6-Methoxy-2-naphthyl)-2-butanone | Relifex | Relif | Apo-Nabumetone | ApoNabumetone | Mebutan | Listran | Gen-Nabumetone | Arthraxan | BRL 14777 | Rhoxal-nabumetone | Rhoxal nabumetone | Relafen | Nabucox
Chemical Information
Molecular Formula C15H16O2
CAS Registry Number 42924-53-8
SMILES CC(=O)CCC1=CC2=C(C=C1)C=C(C=C2)OC
Chemical Structure
ADRs Induced by Drug
*The priority for ADR severity classification is based on FAERS assessment, followed by the most severe level in CTCAE rating. If neither is available, it will be displayed as 'Not available'.
**The 'Not Available' level is hidden by default and can be restored by clicking on the legend twice..
ADR Term ADReCS ID ADR Frequency (FAERS) ADR Severity Grade (FAERS) ADR Severity Grade (CTCAE)
Dermatitis bullous23.03.01.002--
Developmental delay19.07.05.003; 08.01.03.037--Not Available
Diarrhoea07.02.01.0010.000173%
Discomfort08.01.08.003--Not Available
Dizziness02.11.04.006; 24.06.02.007; 17.02.05.0030.000884%
Drug hypersensitivity10.01.01.0010.000381%Not Available
Drug interaction08.06.03.0010.000173%Not Available
Dry mouth07.06.01.002--
Duodenal ulcer07.04.02.002--
Duodenitis07.08.03.001--Not Available
Dysgeusia17.02.07.003; 07.14.03.001--
Dyspepsia07.01.02.0010.000381%
Dysphagia07.01.06.003--
Dyspnoea02.11.05.003; 22.02.01.004--
Dysuria20.02.02.002--
Eosinophilic pneumonia22.01.01.004; 01.02.04.003--Not Available
Eructation07.01.02.003--
Erythema multiforme23.03.01.003; 10.01.03.015--
Fatigue08.01.01.002--
Feeling abnormal08.01.09.014--Not Available
Flatulence07.01.04.002--
Gastric ulcer07.04.03.002--
Gastritis07.08.02.001--
Gastroenteritis11.01.07.004; 07.19.03.001--Not Available
Gastrointestinal haemorrhage24.07.02.009; 07.12.02.001--Not Available
Gastrointestinal pain07.01.05.005--
Generalised oedema14.05.06.007; 08.01.07.0040.000173%
Gingivitis11.01.04.013; 07.09.10.002--
Glomerulonephritis membranous20.05.01.0070.000260%Not Available
Glossitis07.14.01.001--Not Available
The 2th Page    First    Pre   2 3 4 5    Next   Last    Total 5 Pages
ADReCS-Target
Drug Name ADR Term Target
Tip:  Drug Name  ADR Term  Protein  Variation  Gene